Published in Proc Natl Acad Sci U S A on December 10, 1996
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A (1998) 2.50
Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15
Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 2.02
Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 1.92
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med (2000) 1.90
B16 as a mouse model for human melanoma. Curr Protoc Immunol (2001) 1.80
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest (2006) 1.59
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med (2009) 1.47
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol (2000) 1.47
Retracted CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection. Cancer Res (2009) 1.41
Immune recognition of self in immunity against cancer. J Clin Invest (2004) 1.27
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2002) 1.12
Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res (2000) 1.12
Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol (2002) 1.09
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer (2005) 1.07
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun (2006) 1.04
Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein. J Exp Med (2004) 0.95
A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine (2009) 0.92
Improved approach to identify cancer-associated autoantigens. Autoimmun Rev (2004) 0.89
Calicum microdomains form within neutrophils at the neutrophil-tumor cell synapse: role in antibody-dependent target cell apoptosis. Cancer Immunol Immunother (2009) 0.87
Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med (2004) 0.86
A continuous-exchange cell-free protein synthesis system based on extracts from cultured insect cells. PLoS One (2014) 0.86
Analysis of the expression of human tumor antigens in ovarian cancer tissues. Cancer Biomark (2010) 0.84
Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours. Br J Cancer (1998) 0.83
Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology (2012) 0.83
Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol (2015) 0.81
Selecting antigens for cancer vaccines. Nat Biotechnol (2012) 0.78
Intraperitoneal immunotherapy: historical perspectives and modern therapy. Cancer Gene Ther (2016) 0.75
DNA vaccines for prostate cancer. Pharmacol Ther (2017) 0.75
A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients. Oncotarget (2016) 0.75
Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: utilization in design of syngeneic immunotherapy models. Proc Natl Acad Sci U S A (1997) 0.75
Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Ann Transl Med (2016) 0.75
A simple method for displaying the hydropathic character of a protein. J Mol Biol (1982) 150.65
Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis. J Biol Chem (1977) 72.51
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
Selection of successive tumour lines for metastasis. Nat New Biol (1973) 5.03
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (1994) 3.96
Human tumor antigens recognized by T lymphocytes. J Exp Med (1996) 3.63
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Cloning and expression of cDNA encoding mouse tyrosinase. Nucleic Acids Res (1986) 3.21
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
Cancer antigens: immune recognition of self and altered self. J Exp Med (1994) 2.97
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65
Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. J Exp Med (1986) 2.55
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 2.34
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol (1994) 2.19
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
"Intrinsic" immunological tolerance in allophenic mice. Science (1967) 2.10
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A (1994) 1.91
Tyrosinases from two different loci are expressed by normal and by transformed melanocytes. J Biol Chem (1991) 1.90
Glycosylation and secretion of human tissue plasminogen activator in recombinant baculovirus-infected insect cells. Mol Cell Biol (1989) 1.87
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86
Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J Cell Biol (1995) 1.76
Tumour antigens. A new look for the 1990s. Nature (1994) 1.56
Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev (1995) 1.38
The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vector. Virology (1990) 1.34
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A (1987) 1.30
Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst (1981) 1.30
Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci U S A (1995) 1.24
A membrane antigen common to human cancer and fetal brain tissues. Cancer Res (1976) 1.19
Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol (1991) 1.13
Dual function of Drosophila cells as APCs for naive CD8+ T cells: implications for tumor immunotherapy. Immunity (1996) 1.11
A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol (1996) 1.08
Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer (1995) 1.01
T-cell antigens in cancer. Proc Natl Acad Sci U S A (1994) 1.01
Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. Proc Natl Acad Sci U S A (1986) 0.97
Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors. Virology (1989) 0.93
Purification of an autoantigenic 75-kDa human melanosomal glycoprotein. Int J Cancer (1991) 0.85
Glycosylation characteristics of pigmentation-associated antigen (GP75): an intracellular glycoprotein of human melanocytes and malignant melanomas. Arch Biochem Biophys (1986) 0.84
Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines. Ann N Y Acad Sci (1993) 0.82
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53
Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A (1998) 2.50
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44
Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med (2000) 2.25
Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 2.02
Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med (1989) 1.98
Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 1.92
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86
Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med (1984) 1.81
Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J Cell Biol (1995) 1.76
Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A (1983) 1.71
Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer (1998) 1.65
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine (2005) 1.59
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. Proc Natl Acad Sci U S A (1982) 1.59
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer (1993) 1.52
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J Exp Med (1983) 1.48
Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med (1984) 1.48
Diagnostic utility of magnetic resonance imaging in malignant melanoma. J Am Acad Dermatol (1992) 1.39
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proc Natl Acad Sci U S A (1985) 1.39
Evaluation of Elispot assays: influence of method and operator on variability of results. J Immunol Methods (2004) 1.36
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34
A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med (1999) 1.33
Murine serum glycoprotein gp70 behaves as an acute phase reactant. J Exp Med (1982) 1.29
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci U S A (2000) 1.26
The biologically active constituents of Ganoderma lucidum (Fr.) Karst. Histamine release-inhibitory triterpenes. Chem Pharm Bull (Tokyo) (1985) 1.26
Retroviral gp70 immune complexes in NZB x NZW F2 mice with murine lupus nephritis. J Exp Med (1981) 1.25
Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res (1985) 1.24
Occupational vitiligo due to paratertiary butylphenol and homologues. Trans St Johns Hosp Dermatol Soc (1971) 1.22
Evidence against Ha-ras-1 involvement in sporadic and familial melanoma. Nature (1987) 1.21
Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin, but not by glycosylation inhibitor, tunicamycin, in human prostate cancer cells. J Cell Biochem (2000) 1.21
A nationwide survey on organic solvent components in various solvent products: Part 1. Homogeneous products such as thinners, degreasers and reagents. Ind Health (1983) 1.18
Low-calorie diet selectively reduces expression of retroviral envelope glycoprotein gp70 in sera of NZB x NZW F1 hybrid mice. J Exp Med (1981) 1.17
Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate (1999) 1.16
Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J Invest Dermatol (2000) 1.15
A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res (1996) 1.15
Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery (2000) 1.15
Urinary cytology and competitive reverse transcriptase-polymerase chain reaction analysis of a specific CD44 variant to detect and monitor bladder cancer. J Urol (1998) 1.14
Induction of high serum levels of retroviral env gene products (gp70) in mice by bacterial lipopolysaccharide. Proc Natl Acad Sci U S A (1981) 1.13
A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med (1993) 1.13
A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol (1999) 1.12
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer (1992) 1.12
Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer (2000) 1.10
Definition of tumor antigens suitable for vaccine construction. Semin Cancer Biol (1995) 1.10
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. Cancer Res (1987) 1.09
A nationwide survey on organic solvent components in various solvent products: Part 2. Heterogeneous products such as paints, inks and adhesives. Ind Health (1983) 1.09
Rate of decrease and half-life of polychlorinated biphenyls (PCBs) in the blood of mothers and their children occupationally exposed to PCBs. Arch Environ Contam Toxicol (1984) 1.09
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin Cancer Res (1999) 1.08
Monoclonal antibody therapies-a 'constant' threat to cancer. Nat Med (2000) 1.06
[A study on work and daily life factors affecting the health of taxi drivers]. Nihon Koshu Eisei Zasshi (1992) 1.06
Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol (1999) 1.06
Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res (2001) 1.05
Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer (1999) 1.05
Two cases of primary neuroblastoma of the kidney in adults. J Urol (1987) 1.04
Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells. Cancer Res (1997) 1.04
Solitary retroperitoneal neurofibroma: a case report. Hinyokika Kiyo (1989) 1.03
Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res (1997) 1.03
Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (brown) locus product. Exp Cell Res (1991) 1.03
Sorting and secretion of a melanosome membrane protein, gp75/TRP1. J Invest Dermatol (1997) 1.03
Assignment of the human TYRP (brown) locus to chromosome region 9p23 by nonradioactive in situ hybridization. Genomics (1992) 1.03
Renal cell carcinoma with extension of tumor thrombus into the vena cava: surgical strategy and prognosis. J Vasc Surg (2001) 1.02
Malignant melanoma of the skin occurring during pregnancy. Cancer (1981) 1.01
Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer (1995) 1.01
In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring. Cytotherapy (2006) 1.01
The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract. Br J Urol (1998) 1.01
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clin Cancer Res (2000) 1.00
Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene (1992) 1.00
Relationship between breast feeding and PCB residues in blood of the children whose mothers were occupationally exposed to PCBs. Int Arch Occup Environ Health (1978) 0.99
Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene (1998) 0.98
Symposium: biological significance of autoxidized and polymerized oils. Lipids (1973) 0.97
Studies on the tissue culture of Stevia rebaudiana and its components; (II). Induction of shoot primordia. Planta Med (1986) 0.97
Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. Proc Natl Acad Sci U S A (1986) 0.97
Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol (1995) 0.97
[Laparoscopic resection of retroperitoneal tumors: report of two cases]. Hinyokika Kiyo (1999) 0.96
Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol (1988) 0.95
A high concentration of Merkel cells in the bulge prior to the attachment of the arrector pili muscle and the formation of the perifollicular nerve plexus in human fetal skin. Arch Dermatol Res (1993) 0.95
Isolation of inhibitors of adenylate cyclase from dan-shen, the root of Salvia miltiorrhiza. Chem Pharm Bull (Tokyo) (1989) 0.95
Prognostic variables in patients who have undergone radical cystectomy for transitional cell carcinoma of the bladder. Jpn J Clin Oncol (2001) 0.95
Sigmoid neobladder in women after radical cystectomy. J Urol (2000) 0.95
Simultaneous determination of six adenyl purines in human plasma by high-performance liquid chromatography with fluorescence derivatization. J Chromatogr B Biomed Sci Appl (2001) 0.95
Three human cell surface antigen systems determined by genes on chromosome 12. Somat Cell Mol Genet (1984) 0.95